IRUBIS

Co-financing
Biotechnology
Health
München, DE
TU Munich BioTech on course for US Expansion: Millions in savings thanks to patented real-time monitoring in drug manufacturing.

Please note

The acquisition of the offered securities and investments is associated with considerable risks and can lead to the complete loss of the invested assets. The expected yield is not guaranteed and may be lower. Whether it is a security or an asset investment can be seen in the description of the investment opportunity.